Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$4.16 USD
+0.12 (2.97%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $4.16 0.00 (0.00%) 4:44 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -225.30 | -200.37 | -207.30 | -146.23 | -68.61 |
Depreciation/Amortization & Depletion | 13.05 | 21.66 | 21.19 | 9.25 | 3.33 |
Net Change from Assets/Liabilities | -46.18 | -71.55 | -56.82 | -40.80 | 254.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 102.12 | 66.31 | 50.20 | 28.10 | 15.75 |
Net Cash From Operating Activities | -156.32 | -183.95 | -192.73 | -149.68 | 205.40 |
Property & Equipment | -10.70 | -16.35 | -61.75 | -18.80 | -11.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 140.34 | 19.25 | 242.96 | -98.24 | -470.50 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 129.65 | 2.91 | 181.21 | -117.04 | -481.70 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.25 | 7.89 | 27.15 | 293.91 | 324.91 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 124.38 | 0.00 | -0.32 | -5.00 |
Net Cash from Financing Activities | 2.25 | 132.27 | 27.15 | 293.59 | 319.92 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -24.43 | -48.78 | 15.63 | 26.86 | 43.62 |
Cash at Beginning of Period | 92.43 | 141.20 | 125.57 | 98.71 | 55.09 |
Cash at End of Period | 68.00 | 92.43 | 141.20 | 125.57 | 98.71 |
Diluted Net EPS | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 |
Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -47.53 | -225.30 | -155.84 | -105.51 |
Depreciation/Amortization & Depletion | NA | 2.57 | 13.05 | 10.61 | 7.55 |
Net Change from Assets/Liabilities | NA | -10.31 | -46.18 | -42.67 | -24.03 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 16.92 | 102.12 | 58.50 | 39.28 |
Net Cash From Operating Activities | NA | -38.35 | -156.32 | -129.39 | -82.71 |
Property & Equipment | NA | -1.51 | -10.70 | -9.40 | -6.62 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 46.02 | 140.34 | 135.84 | 106.92 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 44.51 | 129.65 | 126.44 | 100.30 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.04 | 2.25 | 2.16 | 2.14 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.04 | 2.25 | 2.16 | 2.14 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 6.20 | -24.43 | -0.79 | 19.74 |
Cash at Beginning of Period | NA | 68.00 | 92.43 | 92.43 | 92.43 |
Cash at End of Period | NA | 74.20 | 68.00 | 91.63 | 112.16 |
Diluted Net EPS | NA | -0.33 | -0.48 | -0.35 | -0.33 |